RELATED CONTENT
February 14, 2020 — Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, announced a ...
February 14, 2020 
January 31, 2018 — Varian Medical Systems announced it has signed an agreement to acquire all the outstanding shares of ...
January 31, 2018 
Sirtex Medical Limited announced in December that SIR-Spheres Y-90 resin microspheres have been included as a Category 2A recommended treatment in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for colon cancer and rectal cancer. This designation denotes there is uniform consensus among the NCCN panel that selective internal radiation therapy (SIRT) with yttrium-90 microspheres is an appropriate option in patients with liver dominant, chemotherapy resistant colorectal disease (mCRC). This recommendation places SIR-Spheres Y-90 resin microspheres at the same designation as the recommended mCRC systemic chemotherapeutic regimens.
January 03, 2017 
At the American Society of Clinical Oncology’s (ASCO) annual conference in Chicago, Siemens presented advanced imaging solutions for Selective Internal Radiation Therapy (SIRT), an innovative therapy procedure for inoperable liver cancers. Siemens and collaborating company Sirtex Medical Ltd. demonstrated the solution and jointly hosted an Industry Expert Theater session on the topic at the 2015 ASCO annual meeting, May 29-June 2.
June 01, 2015 
October 1, 2014 — Newly published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer (mCRC) endorse radioembolization, specifically with Yttrium-90 resin microspheres, as a clinically proven technology to "prolong time to liver tumor progression" in mCRC patients who have failed to respond to available chemotherapy options.
October 01, 2014 
The SIR-Sphere by Sirtex is a radioactive polymer sphere that emits beta radiation and is the only FDA-approved ...
May 21, 2007